Overview
The VPS13 family (VPS13A, VPS13B, VPS13C, VPS13D) constitutes a unique class of bridge-like lipid transfer proteins (LTPs) that span between organelles, creating contact sites where lipids can be directly transferred without vesicular intermediates. VPS13A (linked to chorea-acanthocytosis) and VPS13C (linked to autosomal recessive Parkinson's disease) represent particularly compelling therapeutic targets because they directly connect endoplasmic reticulum (ER) dynamics to mitochondrial health, lysosomal function, and neuronal survival — all core pillars of neurodegeneration. Genetic validation is strong: VPS13A loss-of-function causes adult-onset progressive movement disorder with neurodegeneration, and VPS13C mutations cause early-onset PD with rapid progression. This therapy proposes small-molecule modulators or gene therapy to restore VPS13-dependent lipid transport and organelle contact site function as a disease-modifying approach across multiple proteinopathies[@ramrath2023][@sipioni2021].
Target
- Primary Targets: VPS13A (CHAC1), VPS13C, VPS13D
- Target Type: Protein-protein interaction stabilizer / lipid transfer activity enhancer
- Expression: Brain-enriched, particularly in neurons; high expression in basal ganglia, cortex, and cerebellum
- Localization: ER-resident, forming bridges to mitochondria (MAMs), lysosomes, and peroxisomes
Mechanistic Rationale
The VPS13 family operates at the intersection of several critical neurodegenerative pathways:
...Overview
The VPS13 family (VPS13A, VPS13B, VPS13C, VPS13D) constitutes a unique class of bridge-like lipid transfer proteins (LTPs) that span between organelles, creating contact sites where lipids can be directly transferred without vesicular intermediates. VPS13A (linked to chorea-acanthocytosis) and VPS13C (linked to autosomal recessive Parkinson's disease) represent particularly compelling therapeutic targets because they directly connect endoplasmic reticulum (ER) dynamics to mitochondrial health, lysosomal function, and neuronal survival — all core pillars of neurodegeneration. Genetic validation is strong: VPS13A loss-of-function causes adult-onset progressive movement disorder with neurodegeneration, and VPS13C mutations cause early-onset PD with rapid progression. This therapy proposes small-molecule modulators or gene therapy to restore VPS13-dependent lipid transport and organelle contact site function as a disease-modifying approach across multiple proteinopathies[@ramrath2023][@sipioni2021].
Target
- Primary Targets: VPS13A (CHAC1), VPS13C, VPS13D
- Target Type: Protein-protein interaction stabilizer / lipid transfer activity enhancer
- Expression: Brain-enriched, particularly in neurons; high expression in basal ganglia, cortex, and cerebellum
- Localization: ER-resident, forming bridges to mitochondria (MAMs), lysosomes, and peroxisomes
Mechanistic Rationale
The VPS13 family operates at the intersection of several critical neurodegenerative pathways:
1. ER-Mitochondria Lipid Transfer and Calcium Homeostasis
VPS13 proteins create stable contact sites between the ER and mitochondria (mitochondria-associated membranes, MAMs). At these sites, they transfer phospholipids (phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol) from the ER to mitochondria — a process essential for mitochondrial membrane biogenesis, respiratory chain function, and calcium signaling[@hung2021]. VPS13A deficiency disrupts MAM integrity, causing:
- Impaired phosphatidylserine transfer → defective mitochondrial membranes
- Disrupted ER-mitochondria Ca²⁺ transfer → mitochondrial Ca²⁺ overload and mtDNA damage
- Reduced mitochondrial dynamics and increased fragmentation
2. VPS13A → Chorea-Acanthocytosis (ChAc)ChAc is an autosomal recessive disorder caused by VPS13A mutations (primarily nonsense/truncating). It presents with:
- Huntington disease-like chorea and psychiatric symptoms
- Acanthocytosis (spiky RBCs due to membrane lipid defects)
- Progressive basal ganglia degeneration, especially caudate and putamen
- Adult onset with 10-20 year progression to severe disability
The connection: VPS13A is essential for neuronal morphology maintenance (especially neurite length and branching), process formation, and synaptic terminal integrity. Loss of VPS13A causes:
- Neuronal process retraction and degeneration
- Mitochondrial fragmentation in neurites
- Impaired mitophagy → accumulation of damaged mitochondria
- Progressive striatal neurodegeneration[@schwandt2023][@dawson2010]
3. VPS13C → Autosomal Recessive Parkinson's DiseaseLoss-of-function mutations in VPS13C cause early-onset PD (median onset ~45 years) with:
- Rapid progression to motor symptoms
- Cognitive decline in most patients
- Substantia nigra dopaminergic neuron loss
- Lewy pathology in some cases
VPS13C localizes to ER-lysosome contact sites where it mediates lipid transfer essential for lysosomal membrane composition and function. VPS13C deficiency causes:
- Lysosomal lipid accumulation and enlargement
- Impaired lysosomal proteolytic capacity
- Increased α-synuclein aggregation susceptibility
- ER stress and mitochondrial dysfunction[@sipioni2021][@lesage2023]
4. VPS13D → Mitochondrial Dynamics and Stress ResponseVPS13D interacts with peroxisomes and regulates mitochondrial metabolism. Its knockdown causes:
- Mitochondrial fragmentation and loss of membrane potential
- Reduced oxidative phosphorylation capacity
- Increased reactive oxygen species (ROS)
- Impaired mitophagy initiation
VPS13D is particularly important under metabolic stress conditions, suggesting it may be a resilience factor that could be therapeutically enhanced[@kumar2022].
Mermaid diagram (expand to render)
Cross-links to relevant mechanisms:
- [ER-Mitochondria Contact Sites](/mechanisms/er-mitochondria-contact-sites)
- [Lysosomal Function and Neurodegeneration](/mechanisms/lysosomal-function-neurodegeneration)
- [Mitochondrial Dynamics in Parkinson's Disease](/mechanisms/mitochondrial-dynamics-parkinsons-disease)
- [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
- [Chorea-Acanthocytosis](/diseases/chorea-acanthocytosis)
Rubric Score
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 9/10 | VPS13 family as drug targets is underexplored; lipid transfer protein modulation is a first-in-class mechanism for neurodegeneration |
| Mechanistic Rationale | 9/10 | VPS13A causes ChAc (genetic), VPS13C causes PD (genetic), VPS13D regulates mitophagy; all three validated in human disease and animal models |
| Addresses Root Cause | 8/10 | Organelle contact site dysfunction underlies multiple downstream pathologies (mitochondrial failure, lysosomal impairment, ER stress) — true upstream convergence point |
| Delivery Feasibility | 6/10 | Gene therapy (AAV-VPS13A/C) is primary approach for loss-of-function; small-molecule contact site stabilizers are emerging but less mature |
| Safety Plausibility | 8/10 | Haploinsufficiency may be sufficient for therapeutic effect (VPS13A heterozygous carriers show no obvious disease); overexpression of native protein is lower risk than enzyme inhibition |
| Combinability | 9/10 | Combines with mitophagy enhancers (PINK1/Parkin), GCase activators (lyso ER function), and anti-aggregation approaches |
| Biomarker Availability | 7/10 | Mitochondrial morphology (imaging), lysosomal function assays, VPS13 protein levels in patient-derived neurons, NfL for tracking progression |
| De-risking Path | 7/10 | iPSC models from ChAc and VPS13C-PD patients available; VPS13A knockout mice recapitulate key phenotypes; clear readouts for target engagement |
| Multi-disease Potential | 9/10 | VPS13A covers ChAc and potentially HD; VPS13C covers PD and DLB; VPS13D has broad relevance to AD, PD, and ALS; lipid transport is universally important |
| Patient Impact | 8/10 | VPS13-linked diseases are severe and currently without disease-modifying options; targeting the root cause of a monogenic disease offers high impact |
| Total | 80/100 | |
De-risking Path
Phase 1 — Target validation in patient iPSC neurons: Establish VPS13A/C/D patient iPSC lines (ChAc, VPS13C-PD, age-matched controls); validate lipid transfer assay, mitochondrial morphology, lysosomal function as readouts
Phase 2 — Small-molecule screening for contact site stabilizers: High-content imaging screen for compounds that restore ER-mitochondria contact site morphology in VPS13-deficient neurons; counter-screen for toxicity
Phase 3 — AAV-VPS13A gene therapy: Design AAV9 or AAV5 capsid for CNS delivery; test VPS13A expression, functional rescue (lipid transfer, mitochondrial health), and dose-response in mouse models
Phase 4 — Lead optimization and IND-enabling studies: Optimize AAV construct for full-length VPS13A expression, biodistribution to basal ganglia, and safety pharmacology
Phase 5 — Clinical path: ChAc as initial indication (clear genetic causation, high unmet need); VPS13C-PD as second indication; potential for rare disease accelerated approval pathwayDisease Coverage
| Disease | Relevance | Rationale |
|---------|-----------|-----------|
| Chorea-Acanthocytosis | Very High | Direct causative gene; VPS13A LOF is the disease mechanism[@schwandt2023] |
| Parkinson's Disease (VPS13C-linked) | Very High | VPS13C mutations cause autosomal recessive PD with early onset and rapid progression[@lesage2023] |
| Huntington's Disease | Medium | Shared basal ganglia vulnerability; VPS13A dysfunction models show similar striatal degeneration patterns |
| Parkinson's Disease (sporadic) | Medium | VPS13C variants may be risk factors; VPS13D variants may influence mitochondrial resilience |
| Alzheimer's Disease | Medium | ER-mitochondria dysfunction is a hallmark of AD; VPS13D regulates mitochondrial metabolism relevant to neuronal bioenergetics[@kumar2022] |
| Dementia with Lewy Bodies | Medium | Lysosomal dysfunction and α-synuclein aggregation — both downstream of VPS13C deficiency |
| ALS/FTD | Low-Medium | Mitochondrial dysfunction is central; VPS13D ortholog mutants cause neurodegeneration in flies |
Combination Therapy Potential
- With PINK1/Parkin pathway activators: VPS13D and PINK1/Parkin converge on mitophagy regulation; combined enhancement could restore mitochondrial quality control
- With GCase activators (ambroxol): VPS13C dysfunction impairs lysosomal lipid composition; GCase activators compensate for downstream lysosomal deficiency
- With autophagy inducers (TFEB activators): TFEB promotes lysosomal biogenesis; VPS13C supports lysosomal function — combined approach addresses both biogenesis and function
- With NAD+ precursors: Supports ER and mitochondrial NAD+-dependent enzymes; enhances overall organelle health in VPS13-deficient cells
Related NeuroWiki Pages
- VPS13A Gene
- VPS13C Gene
- ER-Mitochondria Contact Sites
- Mitochondria-Associated Membranes (MAMs)
- Lysosomal Function and Neurodegeneration
- Chorea-Acanthocytosis
- Mitochondrial Dynamics in Parkinson's Disease
- PINK1/Parkin Pathway
- Lipid Metabolism in Neurodegeneration
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Chorea-Acanthocytosis](/diseases/chorea-acanthocytosis)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
External Links
- [PubMed VPS13](https://pubmed.ncbi.nlm.nih.gov/?term=VPS13+neurodegeneration)
- [Orphanet: Chorea-Acanthocytosis](https://www.orpha.net/en/diseases/chorea-acanthocytosis)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Action Plan
1. Next Experiment Design
Primary Goal: Validate VPS13A/C as therapeutic targets in patient-derived neurons
- In vitro model: iPSC-derived neurons from VPS13A-mutant ChAc patients and VPS13C-mutant PD patients
- Readouts:
- ER-mitochondria contact site number and morphology (MitoTracker + ER tracker confocal imaging)
- Mitochondrial morphology (mt-Keima, TOMM20 staining)
- Lysosomal function (Lysotracker, Cathepsin B activity)
- Lipid transfer assay (ER-to-mitochondria phosphatidylserine transfer)
- Neuronal process integrity (MAP2, Tau staining)
- Timeline: 6 months for iPSC differentiation + 3 months treatment + 1 month analysis
2. Lead Compound Generation
- Small-molecule approach: Screen for compounds that increase ER-mitochondria contact site density or enhance VPS13 lipid transfer activity
- Gene therapy approach: Design and test AAV-VPS13A and AAV-VPS13C constructs for CNS delivery
- Combination: Establish readouts for both approaches to prioritize based on efficacy
3. Biomarker Strategy
- Develop CSF or plasma NfL as progression marker for clinical trials
- Establish VPS13 protein levels and phosphorylation state as pharmacodynamic biomarker
- Use mitochondrial morphology in patient-derived neurons as target engagement biomarker